-+ 0.00%
-+ 0.00%
-+ 0.00%

Cybin’s Helus Pharma prices US$50 million follow-on share offering at US$4.85 per share

PUBT·06/24/2026 10:01:39
Listen to the news
Cybin’s Helus Pharma prices US$50 million follow-on share offering at US$4.85 per share
  • Cybin’s Helus Pharma unit priced a US$50 million underwritten follow-on offering of 10,309,280 common shares at US$4.85 each.
  • Closing is expected June 25, 2026, subject to customary conditions.
  • Cantor Fitzgerald, Barclays named joint bookrunners; Bloom Burton Securities, Lucid Capital Markets listed as lead managers.
  • Proceeds earmarked for HLP003 Phase 3 program in major depressive disorder, HLP004 in generalized anxiety disorder, other pipeline work, working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240601PRIMZONEFULLFEED9751769) on June 24, 2026, and is solely responsible for the information contained therein.